In an alternate submitting, the corporate mentioned sure batches of semaglutide have been discovered to be out of specification as a consequence of a problem related to the API used within the product. It added that an investigation is underway to determine the basis trigger and that acceptable measures are being taken to make sure product high quality.
Dr Reddy’s mentioned industrial provides of the product will probably be delayed till the problem is resolved. The corporate clarified that the event has no affect on affected person security or on the product’s present world regulatory filings. It additionally reiterated its dedication to making sure dependable world provides of the metabolic remedy.
Additionally learn: Margin revival, Semaglutide launch to drive Dr Reddy’s progress momentum in FY27Dr Reddy’s additional mentioned its administration will host a convention name to debate the event and reply questions from contributors.
The disclosure comes lower than two months after Dr Reddy’s commercially launched its oral semaglutide pill underneath the model identify Obeda in India for the remedy of type-2 diabetes. The once-daily oral drug is out there in 3 mg, 7 mg and 14 mg strengths, priced at Rs 99, Rs 135 and Rs 225 per pill, respectively.
The corporate had positioned the launch as a key milestone in constructing its GLP-1 portfolio after additionally changing into one of many first firms to launch a generic once-weekly injectable semaglutide in India following the expiry of the related patent earlier this yr.
Dr Reddy’s This fall snapshot
The pharma large reported 86% year-on-year (YoY) decline in consolidated web revenue to Rs 221 crore for the January-March quarter of FY26, as in opposition to Rs 1,587 crore within the year-ago interval, main to focus on worth cuts by brokerages.
Its income from operations, in the meantime, fell 12% YoY to Rs 7,516 crore in the course of the quarter underneath overview, from Rs 8,506 crore reported within the corresponding quarter of the earlier monetary yr.
Learn extra: Dr Reddy’s launches generic Semaglutide injection, standard weight-loss drug, in Canada
The decline in quarterly earnings was totally on account of diminished gross sales of Lenalidomide, worth erosion in North America and Europe Generics and a one-time SSA affect.
Dr Reddy’s share worth has remained flat in 2026, up 2% YTD. Within the final 5 years, the inventory has delivered a return of 17%.
(Disclaimer: Suggestions, options, views and opinions given by the consultants are their very own. These don’t characterize the views of The Financial Instances)
